Q-omics provides the consensus-scored ARL8B profile across patient tissues and cancer cell-line models. ARL8B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ARL8B is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, ARL8B protein abundance shows 24,027 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, and GBM as cancer lineages where ARL8B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL8B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL8B survival associations across molecular data types. ARL8B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL8B RNA expression–survival associations across cancer types. High ARL8B expression shows unfavorable associations in LIHC, MESO, KICH and SCLC, but favorable associations in KIRC and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ARL8B RNA expression.
This table summarizes ARL8B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARL8B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL8B shows lower tumor expression in KIRC and LUAD and higher tumor expression in LIHC, BLCA, BRCA and HNSC. The LIHC box plot shows higher ARL8B RNA expression in tumor versus normal tissue (log2 FC = +1.032, t-test p < 0.001).
This table shows molecular features associated with ARL8B in patient tissues and cancer cell lines. In patient samples, ARL8B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARL8B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and CNS.
